Comparative Pharmacology
Head-to-head clinical analysis: MOTPOLY XR versus MYFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTPOLY XR versus MYFED.
MOTPOLY XR vs MYFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MOTPOLY XR is a combination of an opioid agonist (morphine) and an opioid antagonist (naltrexone). The extended-release formulation allows for sequential release: an initial morphine dose followed by naltrexone, which mitigates opioid-induced adverse effects by antagonizing mu-opioid receptors in the gastrointestinal tract without affecting central analgesia.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Adults: 10 mg orally once daily, with or without food.
500 mg orally twice daily with meals.
None Documented
None Documented
Terminal half-life 12–15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
3-5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~60% unchanged; biliary/fecal: ~25% as metabolites; <5% unchanged in feces.
Primarily renal (85-90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal excretion (5-10%).
Category C
Category C
Decongestant/Antihistamine Combination
Decongestant